TrialSignal
Clinical trial intelligence report
A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT01977482
Status
COMPLETED
Phase
Phase IIB
Sponsor
GlaxoSmithKline
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the dose-response relationship, safety, and efficacy of GSK1278863 in maintaining hemoglobin levels in hemodialysis-dependent subjects with anemia due to chronic kidney disease. The study aimed to optimize dosing regimens for future Phase 3 trials.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT01977482
Indication
Anaemia
Modality
small molecule
Target
GSK1278863 for anemia in hemodialysis-dependent chronic kidney disease patients
Intervention
GSK1278863, Placebo, rhEPO
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.